Top in GI: Entyvio, endoscopic sleeve gastroplasty

A recent study showed that Entyvio was associated with higher rates of ulcerative colitis remission than anti-TNF agents. It was the top story in gastroenterology last week.

Another top story was about the long-term safety and efficacy of endoscopic sleeve gastroplasty among patients with obesity.

Read these and more top stories in gastroenterology below:

Entyvio produces higher UC remission rates than anti-TNF

Patients with ulcerative colitis who received Entyvio (vedolizumab, Takeda) in routine practice experienced higher rates of remission than those treated with anti-TNF agents, according to study results. Read more.

Endoscopic sleeve gastroplasty safe, effective for long-term obesity treatment

Patients with obesity treated with endoscopic sleeve gastroplasty achieved durable results for at least 5 year after the procedure, according to study results. Read more.

Leaders in GI need to be ‘part of the solution not the problem’

In his presentation for the American Society for Gastrointestinal Endoscopy’s virtual GI Outlook conference, Charles M. Nunn, Jr., MD, CPE, MMM, FACPE, offered six pearls for gastroenterologists on how to be the best leader at their practice or institution. Read more.

IBD risk increases among first-degree relatives

The risk for developing inflammatory bowel disease was increased among first-degree relatives of individuals who already had the disease, according to study results. Read more.

Screening delays due to COVID-19 predicted to increase CRC mortality by 12%

Screen delays due to SARS-C0V-2 would significantly increase advanced colorectal cancer cases and mortality if lasting beyond 12 months, according to results presented at UEG Week Virtual Press Briefing. Read more.